Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: ADEL 7 who wrote (222)	11/18/1998 2:10:00 PM
From: Richard Huth	Respond to of 1386

With previous posts I sometimes felt like swimming against a tide being a bit more sceptical about the short-term outlook. I continue to believe that we are not going to see a partner for HU211 before Q3'99, perhaps later. As BOL is slowing down NDA for Alrex/Lotemax in Europe liquidity is becoming a matter again (as warned before), because PARS is missing both, milestones and revenues. Mgt. warned of slow revenue growth in both products in Q4'98. This could well lead into Q1'99. Especially as we still miss the co-partner - and heaven knows when we are going to hear something about it. Keeping the spending flat might be a solution for the short run, but PARS cannot afford keeping R&D on low level for a long time. Wall Street is full of promising companies, that have nothing big out yet (and PARS has neither). The rosy picture of PARS (based on real facts: revenues and earnings) lies far in the future, potential - not proved - blockbusters 4-7 years away. With the big risk laying just ahead, why should WS like PARS right now? So we should take into account seeing PARS dipping below $1,5, if nothing positive shows up within the next future. As longer it takes to move up again, the more nervous investors we are going to see - and we cannot buy all the shares that will be sold. -Richard (sold none)